Trial · NCT01634243
Outcomes11
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Maintenance Dose of the SPM962 | Up to 12 weeks after dosing | Subjects in the safety analysis set who entered the maintenance period | participants | NUMBER |
| SECONDARY | Incidence and Severity of Adverse Events, Vital Signs, and Laboratory Parameters | Up to 12 weeks after dosing | Safety analysis set | participants | NUMBER |
| SECONDARY | Total of Unified Parkinson's Disease Rating Scale (UPDRS) Part 2 Sum Score and Part 3 Sum Score for Early Parkinson's Disease Without Concomitant L-dopa Therapy | baseline, 12 weeks after dosing | Efficacy analysis set, last observation carried forward (LOCF) | Scores on a scale | MEAN |
| SECONDARY | UPDRS Part 3 Sum Score for Advanced Parkinson's Disease With Concomitant L-dopa Therapy | baseline, 12 weeks after dosing | Efficacy analysis set, LOCF | Scores on a scale | MEAN |
| SECONDARY | UPDRS Part 2 Sum Score for Early Parkinson's Disease Without Concomitant L-dopa Therapy | Baseline, 12 weeks after dosing | Efficacy analysis set, LOCF | Scores on a scale | MEAN |
| SECONDARY | UPDRS Part 3 Sum Score for Early Parkinson's Disease Without Concomitant L-dopa Therapy | Baseline, 12 weeks after dosing | Efficacy analysis set, LOCF | Scores on a scale | MEAN |
| SECONDARY | UPDRS Part 2 Sum Score (on State) for Advanced Parkinson's Disease With Concomitant L-dopa Therapy. | Baseline, 12 weeks after dosing | Efficacy analysis set, LOCF | Scores on a scale | MEAN |
| SECONDARY | UPDRS Part 2 Sum Score (Off State) for Advanced Parkinson's Disease With Concomitant L-dopa Therapy. | Baseline, 12 weeks after dosing | Efficacy analysis set, LOCF | Scores on a scale | MEAN |
| SECONDARY | UPDRS Part 2 Sum Score (Average Score of on State and Off State) for Advanced Parkinson's Disease With Concomitant L-dopa Therapy | Baseline, 12 weeks after dosing | Efficacy analysis set, LOCF | Scores on a scale | MEAN |
| SECONDARY | Total of UPDRS Part 2 Sum Score (Average Score of on State and Off State) and Part 3 Sum Score for Advanced Parkinson's Disease With Concomitant L-dopa Therapy | Baseline, 12 weeks after dosing | Efficacy analysis set, LOCF | Scores on a scale | MEAN |
| SECONDARY | Off Time for Advanced Parkinson's Disease With Concomitant L-dopa Therapy | Baseline, 12 weeks after dosing | Subjects with measurable off time data at baseline and after dosing, LOCF | Hours | MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01634243/outcomes